本期内容提示:
1、一大波核心仓位出现建仓机会,优先考虑哪些?
2、又一只有翻倍潜力的成长股临近理想建仓区;
3、$Rxi Pharmaceuticals Corp(PHIO)$ 数据不错,可否追涨?
$恒瑞医药(SH600276)$ $华东医药(SZ000963)$查看全文
Replix锐璞美股2021-03-01 21:16
$Phio Pharmaceuticals(PHIO)$ PHIO PHARMACEUTICALS AND AGONOX, INC. ANNOUNCE COLLABORATION ON CLINICAL DEVELOPMENT OF NOVEL T CELL-BASED CANCER IMMUNOTHERAPIES
Under the terms of the collaboration agreement, AgonOx will receive financial support for the clinical trial from...查看全文
Replix锐璞美股2021-02-18 14:08
$Phio Pharmaceuticals(PHIO)$ 公司增发完毕,看看是否能翻身。
$基因进化ETF-ARK(ARKG)$ $富途控股(FUTU)$查看全文
$Phio Pharmaceuticals(PHIO)$ 8-K Current report, items 5.02 and 9.01 Accession Number: 0001683168-22-006665 Act: 34 Size: 215 KB 网页链接
$Phio Pharmaceuticals(PHIO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-22-051302 Size: 4 KB 网页链接
$Phio Pharmaceuticals(PHIO)$ 8-K Current report, item 3.01 Accession Number: 0001683168-22-006086 Act: 34 Size: 200 KB 网页链接
$Phio Pharmaceuticals(PHIO)$ 8-K Current report, item 5.07 Accession Number: 0001683168-22-005634 Act: 34 Size: 207 KB 网页链接
$Phio Pharmaceuticals(PHIO)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0001683168-22-005566 Act: 34 Size: 262 KB 网页链接
$Phio Pharmaceuticals(PHIO)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0001683168-22-005565 Act: 34 Size: 3 MB 网页链接
$Phio Pharmaceuticals(PHIO)$ DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material Accession Number: 0001683168-22-004729 Act: 34 Size: 688 KB 网页链接
$Phio Pharmaceuticals(PHIO)$ DEF 14A Other definitive proxy statements Accession Number: 0001683168-22-004728 Act: 34 Size: 563 KB 网页链接
$Phio Pharmaceuticals(PHIO)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0001683168-22-003517 Act: 34 Size: 251 KB 网页链接
$Phio Pharmaceuticals(PHIO)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0001683168-22-003516 Act: 34 Size: 3 MB 网页链接